This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. Financial Results for the First Quarter of Fiscal Year Ending March 31, 2025
August 9, 2024 Stock Exchange Listings : Tokyo Stock Exchange (Note: Amounts below are rounded down to the nearest million yen) 1. Consolidated Financial Highlights for the Interim Period Ended June 2024 (From April 1, 2024 to June 30, 2024) (1) Consolidated operating results
(Note)  Comprehensive income : Three months ended June 30, 2024 : 1,200 million yen [4.1%] Three months ended June 30, 2023 : 1,153 million yen [(24.5)%)
3. Consolidated Forecast for the Year Ending March 2025 (From April 1, 2024 to March 31, 2025)
The aforementioned projections are based on the information currently available, and may contain some uncertainties. The final results might be significantly different from the aforementioned projections due to changes in business conditions. 4. Overview of business result for the first quarter (1) Overview of consolidated business results JMS strives to improve the quality of corporate management and the corporate value, in order ' To be a bridge for the people who give and seek medical care, and to bring a smile to people by contributing to a healthy and better life' under our Founding Spirit of 'For People's Precious Life'. JMS focused on four fields of business activities such as Infusion & Enteral Nutrition, Dialysis, Cardiovascular and Blood Management & Cell Therapy and promotes product development, production and sales. During the consolidated cumulative first quarter, sales of Closed Drug Mixing/Infusion Systems remained strong. Additionally, sales in Japan of Prefilled Syringes and Dysphagia-related products increased due to the drug price revisions and the revision of medical service fees. In overseas markets, in addition to the mainstay Apheresis Kits and Blood Bags, sales of Leukocyte Reduction Filters, a business acquired in the previous fiscal year, increased. As a result of the above, net sales of 16,177 million yen, up by 10.8% / 1,576 million yen (year-over-year), due in part to the increase in yen-denominated sales resulting from the depreciation of the yen. Despite the effect of sales increase, the growth of main products and the price increase from the previous year, Operating profit was 42 million yen (operating loss of I11 million yen in the same period of the previous year) due to the effect of increased sales, despite soaring raw material costs and increased manufacturing expenses. Ordinary profit amounted to 194 million yen (ordinary loss of 73 million yen in the same period of the previous year) due to equity in earnings of affiliates and foreign exchange gains, and after income taxes, net loss attributable to owners of the parent amounted to 92 million yen (net loss attributable to owners of the parent of 260 million yen in the same period of the previous year). Business performance by geographical segment.
(i) Japan
Despite a decrease in sales of medical gloves, sales of Prefilled Syringes, Dysphagia-related products, and Closed Drug Mixing/Infusion Systems were strong, and sales related to the Hemodialysis Business for China increased, resulted in n et sales of 10,705 million yen (up 8.3% year-over-year). Segment profit of 252 million yen (loss of 64 million yen in the same period of the previous year) due to the effect of increased revenue.
(ii) Singapore
In addition to increased sales of Apheresis Kits for North America and Blood Bags for Asia and Africa, the weaker yen also contributed to an increase in yen-denominated sales, resulted in net sales of 5,738 million yen (up 14.1% year-over-year). Segment profit of 40 million yen (loss of 59 million yen in the same period of the previous year), despite the positive effect of increased revenue, due to factors such as the sharp rise in raw material costs and increased labor costs.
(iii) China
Sales of AV Fistula Needles, Hemodialysis Blood Tubing Sets, and Hemodialysis Machines were strong, reflecting continued growth in demand due to market expansion, and net sales of 1,010 million yen (up 4.2% year-over-year) were recorded. Segment loss of 36 million yen (loss of 4 million yen in the same period of the previous year) due to an increase in depreciation expenses associated with capital investment.
(iv) Philippines
Sales of Blood Bags for Asia and AV Fistula Needles for Europe declined, but sales of Infusion Sets and Apheresis Kits for Japan increased, resulting in n net sales of 911 million yen (up 1.3% year-over-year). Segment loss of 149 million yen (segment profit of 14 million yen in the same period of the previous year) due to an increase in labor and manufacturing expenses, despite increased sales.
(v) Germany
Sales of AV Fistula Needles and Blood Bags for Europe declined, resulting in net sales of 938 million yen (down 11.4% year-over-year). Segment profit of 74 million yen (down 43.9% year-over-year) due to the impact of lower sales. (vi) Others Sales of Leukocyte Reduction Filters for China increased, resulting in n net sales of 1,152 million yen (up 13.3% year-over-year) and a segment loss of 12 million yen (profit of 10 million yen in the same period of the previous year).
(2) Overview of the financial condition
Total assets at the end of the first quarter of the current fiscal year decreased 1,116 million yen from the end of the previous fiscal year to 83,592 million yen. Details of assets, liabilities and net assets are as follows.
(Assets)
Current assets decreased 1,918 million yen to 46,746 million yen. This was mainly due to a decrease in cash and deposits resulting from repayment of loans payable. Fixed assets increased by 802 million yen from the end of the previous fiscal year to 36,845 million yen. This was mainly due to an increase in property, plant and equipment.
(Liabilities)
Current liabilities decreased 2,1 82 million yen to 27,747 million yen. This was mainly due to decreases in short- term loans payable and current portion of long-term loans payable. Non-current liabilities increased 68 million yen from the end of the previous fiscal year to 14,100 million yen. This was mainly due to an increase in lease obligations.
(Net assets)
Net assets increased 996 million yen from the end of the previous fiscal year to 41,744 million yen. This was mainly due to changes in foreign currency translation adjustments. The equity ratio increased 1.8 percentage points from the end of the previous fiscal year to 49.7%. (3)Overview of consolidated business forecast Consolidated business forecast for the first half and ending of March 31, 2025 released on May 14, 2024 has not been revised, as the overall business environment remained unclear. JMS (7702) Financial Results for the first Quarter of Fiscal Year Ending March 31, 2025
Consolidated Balance Sheet JMS CO., LTD. and Consolidated Subsidiaries
JMS CO., LTD. and Consolidated Subsidiaries
JMS CO., LTD. and Consolidated Subsidiaries
JMS CO., LTD. and Consolidated Subsidiaries